Literature DB >> 10382845

In vivo dynamic distribution of 131I-glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera.

M Hassan1, A Eskilsson, C Nilsson, C Jonsson, H Jacobsson, E Refai, S Larsson, S Efendic.   

Abstract

The in vivo distribution of glucagon-like peptide-1 (7-36) amide (GLP-1) was studied in a rat model using radiolabeled GLP-1 (131I-GLP-1) depicted by a gamma-camera. The dynamic scan showed a rapid clearance from the blood circulation after an intravenous (i.v.) injection of 131I-GLP-1. After 10 min, the major part of the radioactivity was accumulated in the kidneys, whereas about 9% (of the blood value) was found in the brain. The pharmacokinetic study using 125I-GLP-1 demonstrated a rapid elimination from plasma, with a half-life of 3.3 +/- 0.6 min, a clearance of 117 +/- 15 mL/min, and a distribution volume of 557 +/- 61 mL. The elimination half-lives for the intact 125I-GLP-1 in lungs and kidneys were determined to 3.7 and 3.9 min, respectively. The metabolite GLP-1 (9-36) amide was followed in blood, lung, and kidney. All other organs assumed to contain low molecular weight fragments of GLP-1. The present study suggest that GLP-1 and/or its labeled metabolites cross the blood-brain barrier. Also the kidney plays an essential role in GLP-1 elimination after an i.v. administration, which can be of clinical interest especially in patients with kidney insufficiency who are treated with GLP-1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10382845     DOI: 10.1016/s0969-8051(98)00121-8

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  12 in total

Review 1.  Promising new approaches to the management of obesity.

Authors:  I L Mertens; L F Van Gaal
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 2.  Brain GLP-1 and insulin sensitivity.

Authors:  Darleen Sandoval; Stephanie R Sisley
Journal:  Mol Cell Endocrinol       Date:  2015-02-24       Impact factor: 4.102

3.  The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride.

Authors:  R J Seeley; K Blake; P A Rushing; S Benoit; J Eng; S C Woods; D D'Alessio
Journal:  J Neurosci       Date:  2000-02-15       Impact factor: 6.167

4.  Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs.

Authors:  L Simonsen; J J Holst; C F Deacon
Journal:  Diabetologia       Date:  2006-01-31       Impact factor: 10.122

5.  A Synthetic Heterobivalent Ligand Composed of Glucagon-Like Peptide 1 and Yohimbine Specifically Targets β Cells Within the Pancreas.

Authors:  Leah V Steyn; Kameswari Ananthakrishnan; Miranda J Anderson; Renata Patek; Amy Kelly; Josef Vagner; Ronald M Lynch; Sean W Limesand
Journal:  Mol Imaging Biol       Date:  2015-01-21       Impact factor: 3.488

Review 6.  The Effectiveness of Antidiabetic Drugs in Treating Dementia: A Peek into Pharmacological and Pharmacokinetic Properties.

Authors:  Jiro Ogura; Hiroaki Yamaguchi
Journal:  Int J Mol Sci       Date:  2022-06-11       Impact factor: 6.208

7.  GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents.

Authors:  Jianping Ye; Zheng Hao; Michael B Mumphrey; R Leigh Townsend; Laurel M Patterson; Nicholas Stylopoulos; Heike Münzberg; Christopher D Morrison; Daniel J Drucker; Hans-Rudolf Berthoud
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-01-15       Impact factor: 3.619

8.  68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.

Authors:  Maarten Brom; Wim J G Oyen; Lieke Joosten; Martin Gotthardt; Otto C Boerman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-29       Impact factor: 9.236

9.  Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia.

Authors:  Shinichiro Teramoto; Nobukazu Miyamoto; Kenji Yatomi; Yasutaka Tanaka; Hidenori Oishi; Hajime Arai; Nobutaka Hattori; Takao Urabe
Journal:  J Cereb Blood Flow Metab       Date:  2011-04-13       Impact factor: 6.200

10.  Emerging role of GLP-1 receptor agonists in the treatment of obesity.

Authors:  Lisa M Neff; Robert F Kushner
Journal:  Diabetes Metab Syndr Obes       Date:  2010-07-20       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.